A mechanistic pharmacokinetic–patient-derived organoid (PK–PDO) framework for comparing oxaliplatin HIPEC regimens in peritoneal metastases of colorectal cancer

Pouya Namakshenas, Roxan F.C.P.A. Helderman, Wim Ceelen, H. Petra Kok, Johannes Crezee
European Journal of Pharmaceutical Sciences · Elsevier · 2027-01-01 · DOI: 10.1016/j.ejps.2026.107702

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles